# China NMPA Drug Inspection - Anhui Youxin Pharmaceutical Co., Ltd. - Acanthopanax senticosus

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-youxin-pharmaceutical-co-ltd/1c91dd76-0e41-4fd2-8660-a31788e71d42/
Source feed: China

> China NMPA drug inspection for Anhui Youxin Pharmaceutical Co., Ltd. published March 31, 2021. Drug: Acanthopanax senticosus. The Shaanxi Provincial Drug Administration published its first drug quality bulletin of 2021, reporting that four batche

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Shaanxi Province Drug Quality Bulletin (2021, Issue 1, Serial No. 23)
- Company Name: Anhui Youxin Pharmaceutical Co., Ltd.
- Publication Date: 2021-03-31
- Drug Name: Acanthopanax senticosus
- Inspection Finding: [Characteristics] Does not meet the requirements.
- Action Taken: The relevant municipal (county, district) drug regulatory authorities have taken necessary control measures and are investigating and handling the matter in accordance with relevant laws and regulations.
- Summary: The Shaanxi Provincial Drug Administration published its first drug quality bulletin of 2021, reporting that four batches of traditional Chinese medicine products failed to meet national quality standards. This oversight action was conducted under the province's drug sampling inspection framework to ensure public medication safety and compliance with the 2015 edition of the Chinese Pharmacopoeia. The manufacturers identified in the report include Anhui Yuankang Traditional Chinese Medicine Pieces Co., Ltd., Anhui Sanyitang Traditional Chinese Medicine Pieces Co., Ltd., Bozhou City Traditional Chinese Medicine Slices Factory, and Anhui Youxin Pharmaceutical Co., Ltd. The specific products involved were Earthworm, White Peony Root, Eucommia ulmoides, and Acanthopanax senticosus. The main violations involved failures in the drugs' physical characteristics and general inspection parameters, meaning the samples did not match the visual or technical specifications required by law. Notably, some manufacturers have denied producing the sampled batches, suggesting potential issues with product authenticity. In response, regulatory departments at the municipal and county levels have implemented immediate control measures. These actions include the seizure of non-compliant goods and the initiation of formal investigations to penalize the responsible parties and prevent further distribution of substandard medicine.

Company: https://www.globalkeysolutions.net/companies/anhui-youxin-pharmaceutical-co-ltd/b3f0de2e-d30a-4e8c-badc-f9ebda0ddd61/